Born March 15, 1972,[5] Caroline Quach-Thanh completed medical school in 1995, and a residency in pediatrics in 1998 at the University of Montréal. She then pursued her post-doctoral studies in pediatric infections and microbiology (2002), the a Master's degree in Epidemiology (2003) at McGill University.[6] She is a Merit Seeker Research Chair under Fonds de recherche du Québec - Santé.[7]
She is also a member of the INSPQ’s Québec Immunization Committee, including having served as Chair from March 2015 to June 2019.[13]
Quach-Thanh co-delivered a presentation alongside NACI executive secretary Matthew Tunis at the 2018 Canadian Immunization Conference titled "What's new at NACI?" discussing the expansion of NACI's roles and responsibilities.[14][15]
She previously served as Medical Director of the McGill University Health Centre (MUHC) Vaccine Study Centre, a clinical research program that had (at the time) ran “over 75” studies in vaccines and epidemiology.[17]
COVID-19
In response to criticism and confusion following NACI’s recommendations (such as its changing guidance on the AstraZeneca product), she admitted that the council’s members were exhausted from the totality of their workload.[18]
Quach-Thanh is a member of the COVID-19 Immunity Task Force, serving as Chair of the Vaccine Surveillance Reference Group.[21] After concluding her role at NACI, she participated in a study for the task force evaluating effects of COVID-19 vaccines in children. The Government of Canada provided approximately $1.8 million in funding for the study.[22]
On October 18, 2021, Quach-Thanh was quoted in a press release stating that PCR testing should be used in a school setting for asymptomatic students due to their relative sensitivity, whereas rapid antigen tests should be reserved for children displaying symptoms.[23]
She has contributed to around fifteen epidemiological reports from the Institut national de santé publique du Québec.[25] She has also written several chapters in books on pediatric infections,[26][27] as well as pharmacology.[28]
Her expertise is regularly called on to share important information on new outbreaks of pathogens,[29] and vaccination.[30][31][32]
Quach-Thanh was awarded the Canada Research Chair in Infection Prevention and Control on November 1, 2020.[34] The focus of her project, “from Hospital to Community”, is minimizing healthcare-associated infections as well as evaluating the risks and benefits of vaccine regimens. She was awarded $1,400,000 for the period of November 1, 2020 - October 31, 2027 from the Social Sciences and Humanities Research Council under the Canada Research Chairs Program.[35]
Accolades
In 2014, Quach-Thanh received an award for excellence in research from the Montreal Children's Hospital Foundation, under sponsorship by Pfizer.[36] In 2016, she was awarded the John Embil Mentorship Award in Infectious Diseases by the Canadian Foundation for Infectious Diseases.[37]
She was recognized in 2019 and 2020 among Canada's Most Powerful Women: Top 100, in the Manulife-sponsored category of science and technology.[38][39]
^"ACIP Current Membership Roster". U.S. Centers for Disease Control and Prevention. 2021-02-05. Archived from the original on 2021-06-16. Retrieved 2022-04-18.
^"CIC 2018 Final Program"(PDF). Canadian Immunization Conference. November 2018. Archived(PDF) from the original on 2022-04-06. Retrieved 2022-04-18.
^Quach, Caroline (2018-12-05). "What's new with NACI?"(PDF). Canadian Immunization Conference. Archived(PDF) from the original on 2022-04-18. Retrieved 2022-04-18.